Pfizer Lidocaine Injection Recall: Glass Particulates in Injectable Medication
Pfizer is recalling 3,200 vials of Lidocaine Hydrochloride 2% Injection due to the presence of glass particulates. The injectable medication was distributed nationwide in the US and Puerto Rico.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class I recall. Per the severity rubric, FDA Class I recalls warrant a minimum severity score of 4. Glass particulates in an injectable medication pose a serious risk of injury upon administration, even though no illnesses or injuries have been reported in the source text.
Plain-English summary
Pfizer Inc. is recalling 3,200 vials of Lidocaine Hydrochloride 2% Injection (NDC 0409-4903-11) distributed by Hospira Inc. due to the presence of glass particulates. The affected product is a 2% Lidocaine HCl Injection, USP containing 100mg/5mL (20mg/mL) in glass ABBOJECT Unit of Use Syringes, packaged as 1 vial and injector per carton.
The recalled lot is GH6567 with an expiration date of July 1, 2024. The product was distributed nationwide in the United States and Puerto Rico and was not distributed to government accounts or foreign consignees.
The presence of glass particulates in an injectable medication creates a risk of injection of foreign material into tissue. Consumers should not use the affected medication. Patients and healthcare providers who received this product should contact their pharmacist or healthcare provider immediately with the lot number and expiration date.
The recalled product
- Product
- LIDOCAINE HYDROCHLORIDE (LIDOCAINE HYDROCHLORIDE)
- Brand
- LIDOCAINE HYDROCHLORIDE
- Manufacturer
- Pfizer Inc.
- Category
- Drug — Injectable Medication
- Hazard
- glass-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: GH6567
- Exp. 7/1/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LIDOCAINE HYDROCHLORIDE
- HighLidocaine Hydrochloride Injection Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-04-22
- HighLidocaine Hydrochloride Injection Recalled Nationwide for Sterility Assurance Issues
FDA (Drugs) · 2026-04-22
- SevereLidocaine injection recalled due to glass particulate matter
FDA (Drugs) · 2023-11-15
- SevereLidocaine Hydrochloride Topical Solution recalled for being superpotent
FDA (Drugs) · 2022-01-05
- ModerateLidocaine Hydrochloride Topical Solution Recalled for Superpotency
FDA (Drugs) · 2022-01-05
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27